Showing 4401-4410 of 5957 results for "".
- Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-macular-telangiectasia-type-2/2481217/Neurotech Pharmaceuticals announced positive topline results in two replicative phase 3 clinical trials with their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that res
- Outlook Therapeutics Announces Acceptance of BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-biologics-license-application-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2481206/Outlook Therapeutics announced that the FDA has accepted for filing a Biologics License Application (BLA) for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (AMD). The FDA set
- Vyluma Announces Positive Results From Phase 3 CHAMP Study of NVK002 for Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/Vyluma announced topline results from its phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of this multicenter, international study, performed after 3 years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment fo
- EyeMed Vision Care Names Matt MacDonald Presidenthttps://modernod.com/news/eyemed-vision-care-names-matt-macdonald-president/2481204/EyeMed has appointed Matt MacDonald to the role of President. Mr. MacDonald succeeds Lukas Ruecker who has decided to step down after 9 years for personal reasons. Mr. MacDonald has been with EyeMed since 2013, and most recently served as Chief Operations Officer. Prior to that, he
- Altris Launches New Artificial Intelligence Platform for Automated OCT Scanshttps://modernod.com/news/altris-launches-new-artificial-intelligence-platform-for-automated-oct-scans/2481202/Altris Inc. announced the launch of Altris AI, an artificial-intelligence-powered software platform designed to automate OCT examination. The secure, cloud-based platform provides fast analysis and visualization of 100 pathologies and pathological signs, including rare ones, according to Altris.<
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- DORC Acquires Peregrine Surgical and Completes Acquisition of the Remaining Stake in WEFIShttps://modernod.com/news/dorc-acquires-peregrine-surgical-and-completes-acquisition-of-the-remaining-stake-in-wefis/2481192/DORC announced the acquisition of Peregrine Surgical and the acquisition of the full ownership of WEFIS GmbH following an initial equity investment announced earlier in 2022. Financial terms of the deals were not disclosed. DORC says both acquisitions extend the productio
- Study: Digital Home Monitoring Shows Unique Predictive Value in Disease Progression for AMD Patientshttps://modernod.com/news/study-digital-home-monitoring-shows-unique-predictive-value-in-disease-progression-for-amd-patients/2481190/Notal Vision reported the publication of the second report of the "Analysis of Long-term visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT)" study results in Ophthalmology Retina. The 10-year retrospective study details the importance of digital remote monitor
- Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meetinghttps://modernod.com/news/tarsus-to-present-additional-saturn-2-pivotal-phase-3-trial-data-at-the-american-academy-of-optometry-2022-annual-meeting/2481189/Tarsus Pharmaceuticals announced that additional efficacy results from the Saturn-2 pivotal phase 3 trial of TP-03 (lotilaner ophthalmic solution, 0.25%) in Demodex blepharitis patients will be presented at the upcoming American Academy of Optometry 2022 Annual Meeting in San D
- Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol for the Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-acceptance-of-the-new-drug-application-for-cyclasol-for-the-treatment-of-dry-eye-disease/2481186/Novaliq announced that the FDA has accepted the new drug application (NDA) for CyclASol (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED). The agency completed the filing revi